Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.72 |
| ▸ | EGFR | P00533 | 8/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.72 |
| ▸ | SRC | P12931 | 6/20 | 0.71 |
| ▸ | RAF1 | P04049 | 1/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27437241 | 0.86 | MAP2K1 (0.74) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL20782594 | 0.86 | MAP2K1 (0.67) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL30447144 | 0.86 | MAP2K1 (0.67) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL25682522 | 0.86 | EGFR (0.67) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6381609 | 0.84 | EGFR (1.00) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL5733290 | 0.83 | MAP2K1 (1.00) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6381464 | 0.83 | EGFR (1.00) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6380423 | 0.83 | EGFR (1.00) | MAP2K1EGFRERBB2SRCGAK | |
| SCHEMBL28756490 | 0.83 | MAP2K1 (0.95) | MAP2K1EGFRERBB2SRCRAF1 | |
| SCHEMBL6384543 | 0.83 | EGFR (0.80) | MAP2K1EGFRERBB2SRCRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | MAP2K1 4103/4885EGFR 2429/4885ERBB2 3053/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | MAP2K1 4103/4885EGFR 2429/4885ERBB2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.